Drug intelligence / Profile preview

C2104

Development stage: Unknown
Lead developer: Heel
Administration: Oral

Overview

C2104 is a code name for an experimental drug that has been studied in early phase clinical trials, specifically to assess its pharmacokinetic interactions, safety, and drug tolerance when administered alone and in combination with other agents such as JW0201 and C2103 in healthy adults.[2][3][5] Beyond these studies, no chemical, pharmacological, or mechanistic details about C2104 are provided in publicly available sources. The primary focus has been on evaluating its drug-drug interactions, with no published data on its molecular structure, class, or intended therapeutic target.

Beyond the preview

Go deeper on C2104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on C2104.

Explore the full profile